Megesia Tablets 160mg (Megestrol Acetate)

Adult dose

1. Breast cancer : Administer megestrol acetate orally at a dose of 160mg per day in divided doses. 2. Endometrial cancer : Administer this drug orally at a dose of 40~320mg per day in divided doses. 3. Treatment of anorexia, cachexia, or significant unexplained weight loss in patients with cancer or AIDS : Administer megestrol acetate orally at a dose of up to 800mg once daily. In clinical trials, clinical benefit was demonstrated with megestrol acetate doses of 400~800 mg per day. Treatment should be continued for at least 2 months, an appropriate period for assessing the effect of this drug.

This medication may cause serious risks to the fetus if taken during pregnancy, so it should not be used by women who are pregnant or may become pregnant. In particular, taking this medication or similar progestins during the first four months of pregnancy can lead to fatal harm to the fetus, and it should absolutely not be used. This medication should also not be used for the prevention or treatment of habitual or threatened miscarriage. Furthermore, long-term use of this medication may increase the risk of developing diabetes or worsening existing diabetes, and there is also a risk of adrenal insufficiency. If symptoms of adrenal insufficiency appear, such as dizziness, nausea, vomiting, weakness, etc., immediate consultation with healthcare professionals is necessary. Patients allergic to this medication or with specific genetic issues such as lactose intolerance should not take it. Special caution is required for patients with a history of thromboembolism or diabetes, as it may affect thrombosis or blood sugar control. Various side effects such as breast cancer, endometrial cancer, thrombosis, hypertension, hair loss, rash, weakness, etc., may occur during the use of this medication, and any unusual symptoms should be discussed with a physician. Women who are pregnant or breastfeeding should not use this medication and should stop breastfeeding during treatment. Safety in pediatrics has not been established, so it should not be used in children. No particular harmful symptoms have been reported in cases of overdose, but dialysis is ineffective, so in the event of an overdose, immediate visit to a medical institution is necessary. This medication should be kept out of the reach of children, and it is safer not to transfer it to another container. During the use of this medication, the cause of weight loss should be accurately identified and treated, and caution is needed as the risk of respiratory infections may increase with long-term use.

• Thrombophlebitis
• thromboembolic symptoms
• pulmonary embolism
• glucose intolerance
• heart failure
• nausea
• vomiting
• edema
• sudden uterine bleeding
• dyspnea

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is recommended to maintain the storage temperature between 15 to 25 degrees Celsius at room temperature to preserve the medication's effectiveness for a longer period.

Appearance

White oval-shaped tablet

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle, PTP - 100 tablets/PTP [10 tablets/PTP x 10]